These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21887502)

  • 1. The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
    Morande PE; Zanetti SR; Borge M; Nannini P; Jancic C; Bezares RF; Bitsmans A; González M; Rodríguez AL; Galmarini CM; Gamberale R; Giordano M
    Invest New Drugs; 2012 Oct; 30(5):1830-40. PubMed ID: 21887502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
    Zolnierczyk JD; Błoński JZ; Robak T; Kiliańska ZM; Wesierska-Gadek J
    Ann N Y Acad Sci; 2009 Aug; 1171():124-31. PubMed ID: 19723046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells.
    Qiu L; Liu J; Wang Z; Hu W; Huang Q; Zhou Y
    Oncol Rep; 2015 Sep; 34(3):1239-48. PubMed ID: 26165829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.
    Żołnierczyk JD; Borowiak A; Błoński JZ; Cebula-Obrzut B; Rogalińska M; Kotkowska A; Wawrzyniak E; Smolewski P; Robak T; Kiliańska ZM
    Pharmacol Rep; 2013; 65(2):460-75. PubMed ID: 23744431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
    Rebolleda N; Losada-Fernandez I; Perez-Chacon G; Castejon R; Rosado S; Morado M; Vallejo-Cremades MT; Martinez A; Vargas-Nuñez JA; Perez-Aciego P
    PLoS One; 2016; 11(4):e0154159. PubMed ID: 27101369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
    Paulus A; Masood A; Miller KC; Khan AN; Akhtar D; Advani P; Foran J; Rivera C; Roy V; Colon-Otero G; Chitta K; Chanan-Khan A
    Br J Haematol; 2014 Apr; 165(1):78-88. PubMed ID: 24467634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia.
    Rogalińska M; Błoński JZ; Góralski P; Wawrzyniak E; Hartman M; Rogalska A; Robak P; Koceva-Chyła A; Piekarski H; Robak T; Kiliańska ZM
    Int J Oncol; 2015 Mar; 46(3):1259-67. PubMed ID: 25572009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
    Bellosillo B; Villamor N; Colomer D; Pons G; Montserrat E; Gil J
    Blood; 1999 Oct; 94(8):2836-43. PubMed ID: 10515887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
    Shamaa LA; Hussein Ael-S; Balbaa OA; Farahat NM; Ali MA
    Egypt J Immunol; 2008; 15(1):181-92. PubMed ID: 20306682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes.
    Filip AA; Ciseł B; Wąsik-Szczepanek E
    Clin Exp Med; 2015 Feb; 15(1):73-83. PubMed ID: 24337970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes.
    Adams DJ; Levesque MC; Weinberg JB; Smith KL; Flowers JL; Moore J; Colvin OM; Silber R
    Leukemia; 2001 Dec; 15(12):1852-9. PubMed ID: 11753605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia.
    Risnik D; Colado A; Podaza E; Almejún MB; Elías EE; Bezares RF; Fernández-Grecco H; Seija N; Oppezzo P; Borge M; Gamberale R; Giordano M
    Cancer Immunol Immunother; 2020 May; 69(5):813-824. PubMed ID: 32055920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
    Rogalińska M; Błoński JZ; Komina O; Góralski P; Zołnierczyk JD; Piekarski H; Robak T; Kiliańska ZM; Wesierska-Gadek J
    J Cell Biochem; 2010 Jan; 109(1):217-35. PubMed ID: 19911397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
    Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
    Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine-induced apoptosis in CD19+/CD5+B-CLL cells is a direct and nurse-like-cell independent effect.
    Martinez-Lostao L; Briones J; Martinez-Gallo M; Forné I; Sierra J; Rodriguez-Sanchez JL; Juarez C
    Leuk Lymphoma; 2004 Nov; 45(11):2307-14. PubMed ID: 15512822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising anti-leukemic activity of atorvastatin.
    Żołnierczyk JD; Borowiak A; Hikisz P; Cebula-Obrzut B; Błoński JZ; Smolewski P; Robak T; Kiliańska ZM
    Oncol Rep; 2013 May; 29(5):2065-71. PubMed ID: 23440293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors.
    Shcherbina V; Gordiienko I; Shlapatska L; Ivanivska T; Sidorenko S
    Exp Oncol; 2020 Mar; 42(1):16-24. PubMed ID: 32231196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms.
    Zhang W; Pelicano H; Yin R; Zeng J; Wen T; Ding L; Huang R
    Mol Med Rep; 2015 Nov; 12(5):7374-88. PubMed ID: 26458979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.
    Trimarco V; Ave E; Facco M; Chiodin G; Frezzato F; Martini V; Gattazzo C; Lessi F; Giorgi CA; Visentin A; Castelli M; Severin F; Zambello R; Piazza F; Semenzato G; Trentin L
    Oncotarget; 2015 Dec; 6(39):42130-49. PubMed ID: 26517523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
    Pettitt AR; Sherrington PD; Cawley JC
    Cancer Res; 2000 Aug; 60(15):4187-93. PubMed ID: 10945628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.